[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.52.4. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

March 2019, Vol 5, No. 3, Pages 283-442

Original Investigation

Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era

Abstract Full Text
JAMA Oncol. 2019;5(3):318-325. doi:10.1001/jamaoncol.2018.5625

This population-based study examines the incidence and risks for development of therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) in patients who have received chemotherapy for primary solid cancers.

Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation

Abstract Full Text
has audio
JAMA Oncol. 2019;5(3):326-333. doi:10.1001/jamaoncol.2018.5953

This national survey study of patients with cancer evaluates the association between patient comorbid conditions and cancer clinical trial participation.

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(3):334-342. doi:10.1001/jamaoncol.2018.5152

This phase 1b multicohort study assessed 33 patients with advanced triple-negative breast cancer treated with atezolizumab plus nab-paclitaxel to examine its safety, tolerability, and preliminary clinical activity.

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(3):343-350. doi:10.1001/jamaoncol.2018.5080

This multicenter, phase 2, single-arm trial assesses the activity of cetuximab plus irinotecan as third-line treatment for patients with RAS and BRAF wild-type metastatic colorectal cancer who were initially sensitive to and then resistant to first-line irinotecan- and cetuximab-based therapy.

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial

Abstract Full Text
open access
JAMA Oncol. 2019;5(3):351-357. doi:10.1001/jamaoncol.2018.5428

This phase 1b clinical trial assesses the safety and efficacy of avelumab treatment in a multinational cohort of patients with unresectable, previously treated malignant mesothelioma.

Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non–Small Cell Lung Cancer in the Context of the US Health Care System

Abstract Full Text
JAMA Oncol. 2019;5(3):358-365. doi:10.1001/jamaoncol.2018.5449

This study explores the cost-effectiveness and potential budgetary consequences of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer (NSCLC) in the context of the US health care system.

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines

Abstract Full Text
open access
JAMA Oncol. 2019;5(3):366-375. doi:10.1001/jamaoncol.2018.6012

This study examines HER2 ISH-equivocal breast cancers to asses 2013/2014 American Society of Clinical Oncology and College of American Pathologists guidelines in determining HER2-positive or HER2-negative breast cancers and false-positive results.

Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2019;5(3):376-383. doi:10.1001/jamaoncol.2018.5860

This medical records analysis from a single institution in Japan assesses anti–PD-1 treatment in patients with subclinical advanced non–small cell lung cancer and with or without preexisting autoimmune markers and evaluates potential clinical biomarkers that may be associated with clinical benefit or with immune-related adverse events.

Proportion of Cancer Cases Attributable to Excess Body Weight by US State, 2011-2015

Abstract Full Text
JAMA Oncol. 2019;5(3):384-392. doi:10.1001/jamaoncol.2018.5639

This cross-sectional study analyzes the proportion of cancer cases attributable to excess body weight in each US state using data from several databases.

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

Abstract Full Text
open access
JAMA Oncol. 2019;5(3):393-401. doi:10.1001/jamaoncol.2018.6258

This phase 1b open-label study assesses the efficacy and safety of avelumab, an anti–programmed death ligand 1 agent, in a cohort of patients with previously treated recurrent or refractory ovarian cancer.

Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
open access online only
JAMA Oncol. 2019;5(3):e185335. doi:10.1001/jamaoncol.2018.5335

This secondary analysis of a randomized clinical trial examines the association of modern chemoradiotherapy with survival among patients with stage I to II small cell lung cancer compared with that among patients with stage III small cell lung cancer.

Brief Report

Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology

Abstract Full Text
JAMA Oncol. 2019;5(3):402-405. doi:10.1001/jamaoncol.2018.4640

This study searched ClinicalTrials.gov to examine the reporting rates of research biopsies conducted in oncology clinical trials amd investigates what factors correlate with research biopsy reporting.

Research Letter

Triassic Cancer—Osteosarcoma in a 240-Million-Year-Old Stem-Turtle

Abstract Full Text
JAMA Oncol. 2019;5(3):425-426. doi:10.1001/jamaoncol.2018.6766

This case study documents osteosarcoma in 240-million-year-old stem-turtle, which suggests that cancer is not a modern physiological defect.

Trends in Smoking and e-Cigarette Use Among US Patients With Cancer, 2014-2017

Abstract Full Text
JAMA Oncol. 2019;5(3):426-428. doi:10.1001/jamaoncol.2018.6858

This cross-sectional study of data from the National Health Interview Survey analyzes the prevalence of e-cigarette use in US patients with cancer.

Special Communication

Biospecimens, Research Consent, and Distinguishing Cell Line Research

Abstract Full Text
JAMA Oncol. 2019;5(3):406-410. doi:10.1001/jamaoncol.2018.6988

This Special Contribution discusses newly revised regulations for human research affecting the use biospecimens and makes recommendations to enable ethically appropriate regulation of biospecimen research across the spectrum of cancer research.

Review

Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma: A Review

Abstract Full Text
has active quiz
JAMA Oncol. 2019;5(3):411-421. doi:10.1001/jamaoncol.2018.4604

This narrative review discusses the rationale and results of clinical trials in immunotherapy-based combination therapy for patients with advanced renal cell carcinoma.

JAMA Oncology Clinical Challenge

Hemifacial Hyperhidrosis in a Patient With an Apical Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2019;5(3):422-423. doi:10.1001/jamaoncol.2018.4597

This case report describes an unusual case of hyperhidrosis associated with apical lung cancer with sympathetic nerve involvement.

Viewpoint

Biosimilar Filgrastim Use in the United States vs the European Union and Japan—Why Does It Lag Behind and What Can Be Done?

Abstract Full Text
JAMA Oncol. 2019;5(3):297-298. doi:10.1001/jamaoncol.2018.5636

This Viewpoint discusses obstacles that limit the use of biosimilar filgrastim in the United States compared with countries in the European Union and Japan and discusses strategies that might help biosimilar filgrastim use become more widespread.

The Oncology Care Model and Other Value-Based Payment Models in Cancer Care

Abstract Full Text
JAMA Oncol. 2019;5(3):298-299. doi:10.1001/jamaoncol.2018.5735

This Viewpoint describes the benefits of the Oncology Care Model, Medicare’s first cancer-specific alternative payment model, compared with other value-based payment models.

Patient and Caregiver Consent for Publication of Unidentifiable Case Reports—A Barrier to Medical Education and Patient Care

Abstract Full Text
JAMA Oncol. 2019;5(3):300-301. doi:10.1001/jamaoncol.2018.6202

This Viewpoint argues against policies mandating the patient consent process for publication and institutional review board approval of case studies.

Editorial

Myelodysplastic Syndrome and Acute Myeloid Leukemia Risk Associated With Solid Tumor Chemotherapy

Abstract Full Text
JAMA Oncol. 2019;5(3):303-304. doi:10.1001/jamaoncol.2018.5617

Drivers of Clinical Trial Participation—Demographics, Disparities, and Eligibility Criteria

Abstract Full Text
JAMA Oncol. 2019;5(3):305-306. doi:10.1001/jamaoncol.2018.5949
Editor's Note

Moving Beyond Limited and Extensive Staging of Small Cell Lung Cancer

Abstract Full Text
free access online only
JAMA Oncol. 2019;5(3):e185187. doi:10.1001/jamaoncol.2018.5187
JAMA Oncology Patient Page

Focal Radiation Therapy for Cancer

Abstract Full Text
free access
JAMA Oncol. 2019;5(3):442. doi:10.1001/jamaoncol.2018.5868

This Patient Page defines stereotactic body radiation therapy and describes how and in what situations it is administered to treat certain patients with cancer.

Cancer Care Chronicles

Stripping the Fear of a Fatal Disease—The Cancer Named Herbie

Abstract Full Text
JAMA Oncol. 2019;5(3):302. doi:10.1001/jamaoncol.2018.6283

This article describes the coping mechanism used by a patient with cancer.

Poetry and Oncology

The Best Medicine

Abstract Full Text
JAMA Oncol. 2019;5(3):350. doi:10.1001/jamaoncol.2018.6689
Comment & Response

Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom

Abstract Full Text
JAMA Oncol. 2019;5(3):428. doi:10.1001/jamaoncol.2018.6501

Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom—Reply

Abstract Full Text
JAMA Oncol. 2019;5(3):428-429. doi:10.1001/jamaoncol.2018.6504

Risk of Diabetes Associated With Cancer Development

Abstract Full Text
JAMA Oncol. 2019;5(3):429. doi:10.1001/jamaoncol.2018.6619

Risk of Diabetes Associated With Cancer Development—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(3):429-430. doi:10.1001/jamaoncol.2018.6647

Methodology Flaws and Implications of a Complementary Medicine Study

Abstract Full Text
JAMA Oncol. 2019;5(3):430. doi:10.1001/jamaoncol.2018.6622

Methodology Flaws and Implications of a Complementary Medicine Study

Abstract Full Text
JAMA Oncol. 2019;5(3):430-431. doi:10.1001/jamaoncol.2018.6625

Methodology Flaws and Implications of a Complementary Medicine Study

Abstract Full Text
JAMA Oncol. 2019;5(3):431-432. doi:10.1001/jamaoncol.2018.6628

Methodology Flaws and Implications of a Complementary Medicine Study

Abstract Full Text
JAMA Oncol. 2019;5(3):432. doi:10.1001/jamaoncol.2018.6631

Methodology Flaws and Implications of a Complementary Medicine Study

Abstract Full Text
JAMA Oncol. 2019;5(3):432-433. doi:10.1001/jamaoncol.2018.6640

Methodology Flaws and Implications of a Complementary Medicine Study—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(3):433. doi:10.1001/jamaoncol.2018.6650

Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test

Abstract Full Text
JAMA Oncol. 2019;5(3):433-434. doi:10.1001/jamaoncol.2018.6683

Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(3):434. doi:10.1001/jamaoncol.2018.6686

Questioning Lay Health Worker Influence on Goals-of-Care Documentation and Patient Satisfaction

Abstract Full Text
JAMA Oncol. 2019;5(3):434-435. doi:10.1001/jamaoncol.2018.6855

Questioning Lay Health Worker Influence on Goals-of-Care Documentation and Patient Satisfaction—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(3):435-436. doi:10.1001/jamaoncol.2018.6875
Correction

Error in Figure

Abstract Full Text
free access
JAMA Oncol. 2019;5(3):436. doi:10.1001/jamaoncol.2019.0111
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2019;5(3):291. doi:10.1001/jamaoncol.2018.4744
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2019;5(3):283. doi:10.1001/jamaoncol.2018.4743
×